United Kingdom Computed Tomography - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

The United Kingdom Computed Tomography Market size is estimated at USD 467.43 million in 2024, and is expected to reach USD 635.32 million by 2029, growing at a CAGR of 6.33% during the forecast period (2024-2029).

The COVID pandemic had an adverse effect on market growth. Various research studies have been published to provide insight into the effects of the pandemic. For instance, the COVID-19 pandemic: impact on NHS England PET-CT services and lessons learned is the title of a study that was conducted to determine how the first wave of COVID-19 affected the National Health Service's (NHS) 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) scanning activity in England. The study was published in Nuclear Medicine Communication in February 2021. The analysis found that for the two months of April and May 2020, there was a 32 percent and a 31 percent decline in activity, respectively. Comparing cancer FDG PET-CT cases to non-cancer CT cases, a greater decline was seen. Between January 2020 and June 2020, 50,879 FDG PET-CTs were finished, compared to 52,460 FDG PET-CTs finished during the same time in 2019. Along with its negative effects, COVID-19 has given players the chance to build their presence by releasing new products or advancing clinical research in this area. Due to which, the studied market is expected to recover in future years.

The UK computed tomography market is majorly driven by higher incidences and mortality rates associated with chronic diseases, such as diabetes and cancer. The country's market is also driven by the growing geriatric population, increasing research and development procedures, rising investments, and increasing product launches. According to Globocan 2020, there were 457,960 new cases of cancer in the UK in 2020, and 595,909 instances are anticipated by 2040. The country will employ more CT scanners as a result of the anticipated rise in cancer cases because CT scanners are used to diagnose a variety of cancers. As a result, it is anticipated that the market under study will expand significantly during the next years. Another significant contributing factor to mortality in the nation is diabetes. The country has 5.6 percent prevalence of diabetes, with 2,680,500 people living with the disease, according to the International Diabetes Federation. Due to the fact that diabetes is the primary risk factor for many chronic illnesses, including cancer, this is anticipated to spur market expansion throughout the forecasted period. According to figures provided by the Organization for Economic Co-operation and Development, there were 9 CT scanners per 1,000,000 people in hospitals in the United Kingdom. Due to the growing burden of chronic diseases and the ageing population, more CT scanners are anticipated to be installed across the nation. This is anticipated to stimulate market expansion. Additionally, the National Research Facility (NRF) in Lab-based X-ray Computed Tomography was established in November 2020 with the help of the current facilities from the Universities of Manchester, Southampton, University College London (UCL), University of Warwick, and Diamond Light Source to offer the United Kingdom a special and varied shared capability. The Engineering and Physical Sciences Research Council (EPSRC) provided 10 million euros over 5 years to NRF to build this facility. Therefore, it is anticipated that rising product launches and rising investments in the relevant industry will fuel market expansion.

However, it is anticipated that the market expansion in the United Kindgom will be constrained by the inadequate reimbursement and the high cost of equipment and CT scan procedures.

UK Computed Tomography Market Trends

Oncology Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Growth is anticipated to be boosted by the high prevalence of various cancer kinds and the existence of market players in the nation. Growing initiatives by big companies that could help the market develop in the future are another factor contributing to the expansion of this category. The number of cancer cases is expected to increase, and screening programs for cancer procedures that need computed tomography imaging are expected to increase the demand for computed tomography devices in the nation. For instance, the GLOBOCAN 2020 report was released by the International Agency for Research on Cancer. The analysis estimates that there will be 53,889 new cases of breast cancer in the United Kingdom in 2020. The research also said that 56,780 instances of prostate cancer were anticipated to be diagnosed in 2020. 13,168 men lost their lives to prostate cancer. The demand for computed tomography for diagnosis is anticipated to increase as a result of the high prevalence of various cancer conditions in the United Kingdom. To address the National Health Service (NHS) care backlog in England, the government promised to invest EUR 350 million in the creation of 40 new "one-stop-shops for inspections, scans, and tests" in October 2021. By March 2022, the centers would be completely operational after providing services over the following six months. Such government activities are projected to increase the use of computed tomography scanners to scan for cancer cases, which will fuel the market under study's expansion. In September 2020, Canon Medical System UK distributed 15 mobile CT scanners to National Health Service (NHS) trusts all around the nation. The aforementioned elements and study findings are also anticipated to enhance market expansion in this sector.

UK Computed Tomography Industry Overview

The United Kingdom computed tomography market is moderately competitive and consists of several major players. Some of the companies that are currently dominating the market are Canon Medical Systems, Koning Corporation, GE Healthcare, Planmeca Group (Planmed OY), and Koninklijke Philips NV among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support